Ixekizumab-induced interstitial lung disease: a case report confirmed by transbronchial lung cryobiopsy
Background: Ixekizumab, an interleukin-17A (IL-17A) inhibitor used in psoriasis treatment, has been linked to drug-induced interstitial lung disease (DI-ILD). The pathophysiological mechanisms and histopathological features of this adverse effect remain poorly documented.Case Presentation: A 69-year...
Guardado en:
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Taylor & Francis Group
2024-12-01
|
| Colección: | Journal of Dermatological Treatment |
| Materias: | |
| Acceso en línea: | https://www.tandfonline.com/doi/10.1080/09546634.2024.2424338 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|